Herpes Zoster Duplex Unilateralis as a manifestation of severe lymphopenia in COVID19

Bhargava, Puneet; Singdia, Heena; Mathur, Rachita; Garg, Rohit; Rani, Neha; Nijhawan, Shivi; Kothari, Deepika

doi:10.1002/ejp.1709

Cited by 4 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…geminal nerve after mean duration of 4.5 days following COVID-19 infection. 3 Similar observations were also noted by Shors AR and Bhargava et al 4,5 Interestingly, a much longer latency period (26 days post-COVID)…”

Section: Nofal Et Al Described Four Cases Of Hz Involving Maxillary D...supporting

confidence: 75%

Herpes zoster involving trigeminal nerve: An early cutaneous predictor of COVID‐19—a case series and review of the literature

Sil

Bhanja

Sarkar

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Section: Nofal Et Al Described Four Cases Of Hz Involving Maxillary D...supporting

confidence: 75%

Herpes zoster involving trigeminal nerve: An early cutaneous predictor of COVID‐19—a case series and review of the literature

Sil

Bhanja

Sarkar

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

“…A total of 314 studies were identified. After applying the inclusion and exclusion criteria, 55 studies [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] of VZV manifestations in subjects with SARS-CoV-2 vaccinations or COVID-19 disease were deemed eligible for inclusion. A flow diagram of the selection of the studies is presented in Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Post-herpetic neuralgia, encephalitis-meningitis and vasculitis manifestations were also described in one subject each. The median (IQR) latency time associated with VZV reactivation was 7 days (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). Antiviral prescriptions were made in 30 subjects, the most frequently used being acyclovir.…”

Section: Coronavirus Disease 2019mentioning

confidence: 99%

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Martinez-Reviejo¹,

Adebanjo²,

Chello³

et al. 2022

European Journal of Internal Medicine

View full text Add to dashboard Cite

“…A total of 19 articles with three observational studies and 16 case reports or series were included in the review. 6 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 …”

Section: Resultsmentioning

confidence: 99%

“…A total of 19 articles with three observational studies and 16 case reports or series were included in the review. 6,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] Description of included studies Table 1 describes the main characteristics of three observational studies from the scoping review. Giavedoni et al conducted a retrospective analysis of COVID-19 skin lesions in order to characterize the clinical patterns of the lesions.…”

Section: Data Extraction and Definitionmentioning

confidence: 99%

Characteristics of herpes zoster infection in patients with COVID‐19: a systematic scoping review

Czech

Nishimura

2022

Int J Dermatology

View full text Add to dashboard Cite

Background Although there is literature reporting correlations between varicella zoster virus (VZV) infections and COVID-19, insufficient evidence exists in this regard. This scoping review aims to identify the existing evidence regarding clinical characteristics of primary VZV infection or reactivation in COVID-19. Methods Following the PRISMA Extension for Scoping Reviews, MEDLINE and EMBASE were searched for all peer-reviewed articles with relevant keywords including "Zoster," "Herpes," and "COVID-19" from their inception to November 20, 2021.Results A total of 19 articles with three observational studies and 16 case reports or series were included. Primary VZV infections or reactivation were observed in 25 patients.Forty-eight percent of the patients had disseminated VZV infection. The median time of VZV-related rash after the onset of respiratory symptoms was 7.0 days (interquartile range: 0-18.8). Those with COVID-19 and primary VZV infection or reactivation had low lymphocyte counts with a median of 0.67 9 10 3 /ll. ConclusionThis scoping review identified uncertainty and a lack of strong evidence to see the association between primary VZV infection or reactivation and COVID-19. However, those with COVID-19 may be more likely to have disseminated VZV, which poses an additional challenge from an infection prevention standpoint. Future studies are warranted to determine the association between primary VZV infection or reactivation and long-term consequences related to COVID-19.the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews (PRISMA-ScR). 10,11 Appendix S1 is the PRISMA-ScR checklist of the present study.Search strategy MEDLINE and EMBASE searches were conducted for all peer-reviewed articles from inception to November 20, 2021.

show abstract

Herpes Zoster Duplex Unilateralis as a manifestation of severe lymphopenia in COVID19

Cited by 4 publications

References 5 publications

Herpes zoster involving trigeminal nerve: An early cutaneous predictor of COVID‐19—a case series and review of the literature

Herpes zoster involving trigeminal nerve: An early cutaneous predictor of COVID‐19—a case series and review of the literature

Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights

Characteristics of herpes zoster infection in patients with COVID‐19: a systematic scoping review

Contact Info

Product

Resources

About